viewCello Health PLC

Cello Group’s Scott: Share price still too low despite recent rise

< id="YT_video" object width="560" height="315">

Cello Group (LON:CLL) chief executive Mark Scott claims that his healthcare and consumer strategic marketing group is still undervalued even after several years of share price growth.

He says that while there are a number of quoted health services like it in the States, Cello is the only one on the London market and trades on much lower earnings multiples than its US peers.

He says the main source of growth is organic, but the company will look at potential acquisitions if opportunities arise. 

Quick facts: Cello Health PLC

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...


Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016

2 min read